» Articles » PMID: 19069636

Bone Marrow Cell Transplant Does Not Prevent or Reverse Murine Liver Cirrhosis

Overview
Journal Cell Transplant
Date 2008 Dec 17
PMID 19069636
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

We tested the effect of bone marrow cell (BMC) transplantation in either preventing or reversing cirrhosis on an experimental model of chronic liver disease. Female Wistar rats were fed a liquid alcohol diet and received intraperitoneal injections of carbon tetrachloride (CCl4) over 15 weeks. Ten animals (cell-treated group) received five injections of BMCs during the cirrhosis induction protocol (on the 4th, 6th, 8th, 10th, and 12th weeks) and four animals received the cells after liver injury was established through tail vein. Nine animals (nontreated group) were submitted to the previously described protocols; however, they received vehicle injections. Analyses were performed to verify whether the infusion of cells was effective in preventing the development of cirrhosis in our model of induction, and if the cells could reverse cirrhosis once it was established. Hepatic architecture and fibrotic septa were analyzed in liver slices stained with hematoxilin & eosin and Sirius red, respectively. Fibrosis quantification was measured by Sirius red histomorphometry. Indirect immunofluorescence was performed to detect the amount of tissue transglutaminase 2. Blood analyses were performed to assess liver injury and function by the assessment of alanine aminotransferase and albumin. Ultrasound was performed to analyze the portal vein caliber and presence of ascitis. Cirrhosis features (regenerative nodules and fibrous septa) were observed in histopathology after 15 weeks of continuous hepatic injury in nontreated and cell-treated groups. Collagen content, immunofluorescence analysis, and biochemical and ultrasound parameters were similar in nontreated and cell-treated groups; however, both groups showed significant differences compared to a normal control group. Cell infusions with bone marrow-derived cells seem to be ineffective in improving morphofunctional parameters of the liver when applied to chronic cases either during or after establishment of the hepatic lesion.

Citing Articles

Liver scaffolds obtained by decellularization: A transplant perspective in liver bioengineering.

Dias M, Paranhos B, Dos Santos Goldenberg R J Tissue Eng. 2022; 13:20417314221105305.

PMID: 35756167 PMC: 9218891. DOI: 10.1177/20417314221105305.


Granulocyte Colony-Stimulating Factor Treatment Before Radiotherapy Protects Against Radiation-Induced Liver Disease in Mice.

Ramos I, Dias M, Nunes De Moraes A, Meireles Ferreira F, Souza S, Gutfilen B Front Pharmacol. 2021; 12:725084.

PMID: 34867327 PMC: 8634713. DOI: 10.3389/fphar.2021.725084.


Mesenchymal stem cells suppress hepatic fibrosis accompanied by expanded intrahepatic natural killer cells in rat fibrosis model.

Duman D, Zibandeh N, Ugurlu M, Celikel C, Akkoc T, Banzragch M Mol Biol Rep. 2019; 46(3):2997-3008.

PMID: 30850965 DOI: 10.1007/s11033-019-04736-4.


Current Understanding of Stem Cell and Secretome Therapies in Liver Diseases.

Kim D, Cho G, Han C, Park D, Park H, Woo D Tissue Eng Regen Med. 2019; 14(6):653-665.

PMID: 30603518 PMC: 6171672. DOI: 10.1007/s13770-017-0093-7.


Proceedings of the signature series event of the international society for cellular therapy: "Advancements in cellular therapies and regenerative medicine in digestive diseases," London, United Kingdom, May 3, 2017.

Ciccocioppo R, Santos C, Baumgart D, Cangemi G, Cardinale V, Ciacci C Cytotherapy. 2018; 20(3):461-476.

PMID: 29398624 PMC: 6771025. DOI: 10.1016/j.jcyt.2017.12.004.